期刊
VIRUSES-BASEL
卷 14, 期 2, 页码 -出版社
MDPI
DOI: 10.3390/v14020387
关键词
COVID-19; SARS-CoV-2; variants; vaccine; adjuvant
类别
资金
- National Natural Science Foundation of China [82041025, 92169112]
- Scientific Research Foundation of Zhejiang University City College [J-202106]
This article focuses on the research progress and achievements of adjuvanted COVID-19 subunit and inactivated vaccines, and compares the advantages and disadvantages of different adjuvant formulations, aiming to provide a scientific reference for designing an effective strategy for future vaccine development.
Several countries have made unremitting efforts to develop an optimal vaccine in the fight against coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). With the increasing occurrence of SARS-CoV-2 variants, current vaccines show decreased neutralizing activities, especially towards the Omicron variant. In this context, adding appropriate adjuvants to COVID-19 vaccines can substantially reduce the number of required doses and improve efficacy or cross-neutralizing protection. We mainly focus on research progress and achievements associated with adjuvanted COVID-19 subunit and inactivated vaccines. We further compare the advantages and disadvantages of different adjuvant formulations in order to provide a scientific reference for designing an effective strategy for future vaccine development.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据